Shannon T. Kelley
CIK: 0002034056
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
MADRIGAL PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Aug 17, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct664 shares at avg. $514.97$342K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct360 shares at avg. $431.94$155K - Mar 4, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Award(A)Direct4K shares- - Jan 20, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct263 shares at avg. $490.77$129K - Jan 20, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct429 shares at avg. $501.40$215K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct84 shares at avg. $371.35$31K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct252 shares at avg. $372.44$94K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct190 shares at avg. $375.75$71K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct68 shares at avg. $374.13$25K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct42 shares at avg. $376.62$16K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct458 shares at avg. $358.66$164K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct126 shares at avg. $369.64$47K - Aug 18, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct84 shares at avg. $370.06$31K - Mar 5, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Award(A)Direct3.2K shares- - Mar 3, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct415 shares at avg. $335.00$139K - Jan 17, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct277 shares at avg. $273.41$76K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 17, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 664 | $514.97 | $341,940 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 360 | $431.94 | $155,498 | Direct |
| Mar 4, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Award(A) | 4,017 | - | $0 | Direct |
| Jan 20, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 263 | $490.77 | $129,073 | Direct |
| Jan 20, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 429 | $501.40 | $215,101 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 84 | $371.35 | $31,193 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 252 | $372.44 | $93,855 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 190 | $375.75 | $71,393 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 68 | $374.13 | $25,441 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 42 | $376.62 | $15,818 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 458 | $358.66 | $164,266 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 126 | $369.64 | $46,575 | Direct |
| Aug 18, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 84 | $370.06 | $31,085 | Direct |
| Mar 5, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Award(A) | 3,187 | - | - | Direct |
| Mar 3, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 415 | $335.00 | $139,025 | Direct |
| Jan 17, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 277 | $273.41 | $75,735 | Direct |
1-16 of 16 transactions
About Kelley Shannon T
Kelley Shannon T (SEC CIK 0002034056) files insider reports with the SEC as General Counsel of MADRIGAL PHARMACEUTICALS, INC. (MDGL).
Signal8 holds 7 ownership filings by Kelley Shannon T, all Form 4s, filed between Jan 17, 2025 and Aug 20, 2026. Those filings report 16 transactions, from Jan 17, 2025 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kelley Shannon T's filings is in WEST CONSHOHOCKEN, PA.
Recent filings by Kelley Shannon T
- Aug 17, 2026: Open-market sale of MDGL shares (Form 4, code S).
- Mar 6, 2026: Open-market sale of MDGL shares (Form 4, code S).
- Mar 4, 2026: Grant or award of MDGL shares (Form 4, code A).
- Jan 20, 2026: Open-market sales of MDGL shares (2 lines, Form 4, code S).
- Aug 18, 2025: Open-market sales of MDGL shares (8 lines, Form 4, code S).
Other insiders filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Sibold William John, President and CEO
- REED JOHN C, Director
- Taub Rebecca, Director
- Levy Richard S, Director
- FOUSE JACQUALYN A, Director
- Daly James M, Director